Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 3Neoplasms 2Lymphoma 2Lung Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Nose Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 10fludarabine 7trametinib 6Specimen Handling 6Mycophenolic Acid 6Whole-Body Irradiation 5Sirolimus 5Nivolumab 5Biopsy 5fludarabine phosphate 4Magnetic Resonance Spectroscopy 4dabrafenib 3Prednisone 3Melphalan 3Ipilimumab 3GSK2636771 3Filgrastim 3Electrocardiography 3Crizotinib 3CTLA-4 Antigen 3Busulfan 3palbociclib 2osimertinib 2keyhole-limpet hemocyanin 2capivasertib 2binimetinib 2adavosertib 2X-Rays 2Mesna 2Immunoglobulin G 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hematologic Neoplasms × Positron-Emission Tomography × Clear all
NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 20 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡